Republican and Democratic U.S. senators called for a government analysis of foreign influence in the U.S. pharmaceutical supply chain, saying the coronavirus pandemic has exposed an over-reliance on China and other countries for the production of essential drugs.

A bill to encourage the manufacture of active pharmaceutical ingredients in America was introduced in the U.S. Senate by Senators Marsha Blackburn (R-TN) and Bob Menendez (R-NJ).

U.S. President Donald Trump signed a bill allocating $8.3 billion to bolster the country’s capacity to test for the new coronavirus and fund other measures to stem an outbreak that has infected some 100,000 people worldwide.

The U.S. House of Representatives overwhelmingly approved an $8.3 billion bill to combat the spread of the new coronavirus and develop vaccines for the highly contagious disease, sending it to the Senate for final passage.

With impeachment behind us and the elections looming, both parties are focused on healthcare, the policy topic of greatest concern to voters. More specifically, they are focused on lowering the cost of prescription drugs.

Chants of “H.R. 3” broke out in the House of Representatives chamber during the 2020 State of the Union Address as Democratic lawmakers urged action on the bill passed late last year that could impact the price of prescription medications paid for by government-funded health programs.

PhRMA CEO Stephen Ubl said House Speaker Nancy Pelosi’s plan would be “devastating” to the industry.

U.S. Senator Bernie Sanders unveiled the latest version of his ambitious “Medicare-for-All” plan, moving the healthcare debate among Democratic presidential contenders to center stage in the 2020 race.

Four Democratic U.S. senators introduced a bill that would allow the government to block drug price increases that are unjustified.

Johnson & Johnson said it would take a $13.6 billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.